US 12,187,682 B2
MCT4 inhibitors for treating disease
Kenneth Mark Parnell, Kaysville, UT (US); and John McCall, Boca Grande, FL (US)
Assigned to Vettore, LLC, San Francisco, CA (US)
Filed by Vettore, LLC, San Francisco, CA (US)
Filed on Jun. 19, 2023, as Appl. No. 18/337,313.
Application 16/222,964 is a division of application No. 15/180,623, filed on Jun. 13, 2016, granted, now 10,202,350, issued on Feb. 12, 2019.
Application 18/337,313 is a continuation of application No. 17/481,660, filed on Sep. 22, 2021, granted, now 11,724,989.
Application 17/481,660 is a continuation of application No. 17/030,243, filed on Sep. 23, 2020, granted, now 11,155,522, issued on Oct. 26, 2021.
Application 17/030,243 is a continuation of application No. 16/222,964, filed on Dec. 17, 2018, abandoned.
Claims priority of provisional application 62/174,685, filed on Jun. 12, 2015.
Prior Publication US 2024/0101518 A1, Mar. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 231/12 (2006.01); A61K 31/415 (2006.01); A61K 31/4155 (2006.01); A61K 31/427 (2006.01); A61K 31/4439 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 401/06 (2006.01); C07D 405/12 (2006.01); C07D 409/04 (2006.01); C07D 417/04 (2006.01)
CPC C07D 231/12 (2013.01) [A61K 31/415 (2013.01); A61K 31/4155 (2013.01); A61K 31/427 (2013.01); A61K 31/4439 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 401/06 (2013.01); C07D 405/12 (2013.01); C07D 409/04 (2013.01); C07D 417/04 (2013.01)] 9 Claims
 
1. A method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof, wherein the treatment selectively inhibits activity of the monocarboxylate transporter MCT4, or a mutant thereof, over the monocarboxylate transporter MCT1, or a mutant thereof, comprising the step of administering to the subject a compound of structural Formula I

OG Complex Work Unit Chemistry
and/or a salt thereof, wherein:
A1, A2, and A3 are independently chosen from N and C, wherein at least one of A1, A2, and A3 is N;
L is chosen from a bond and methylene;
W is chosen from

OG Complex Work Unit Chemistry
R4 and R5 are independently chosen from C1-C6alkyl, wherein R4 and R5 together comprise no more than 6 carbons;
X is H;
Y is chosen from alkenyl, alkenylamino, alkyl, aminoalkenyl, aminoalkyl, aryl, cycloalkyl, and heteroaryl, any of which may be optionally substituted with one to three R2 groups each independently chosen from alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, cycloalkoxy, cycloalkylmethoxy, alkylamino, amino, amido, sulfonamido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl; and
Z is chosen from aryl and heteroaryl, either of which may be optionally substituted with one to three R3 groups each independently chosen from alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, alkylamino, amino, amido, sulfonamido, halo, cyano, hydroxy, cycloalkyl, aryl, and heteroaryl.